NCT00988520View on ClinicalTrials.gov

Study of Efficacy, Pharmacokinetics and Safety of Continuous Intravenous Infusion of Org 9426 (Study P05977)

PHASE3CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

May 31, 2003

Primary Completion Date

September 30, 2003

Study Completion Date

September 30, 2003

Conditions

Anesthesia

Interventions

DRUG

Rocuronium bromide

Continuous intravenous infusion initiated at 7 μg/kg/min and adjusted to maintain muscle relaxation

DRUG

Rocuronium bromide

Intubation dose of 0.6 mg/kg injection

DRUG

Rocuronium bromide

Intubation dose of 0.9 mg/kg injection

DRUG

Sevoflurane

0.5-2.0% intravenous maintenance anesthesia

DRUG

Propofol

4010 mg/kg/hr intravenous maintenance anesthesia

All Listed Sponsors

lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT00988520 - Study of Efficacy, Pharmacokinetics and Safety of Continuous Intravenous Infusion of Org 9426 (Study P05977) | Biotech Hunter | Biotech Hunter